Esperion Therapeutics (ESPR) Projected to Post Quarterly Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) will likely be releasing its earnings data before the market opens on Tuesday, March 4th. Analysts expect Esperion Therapeutics to post earnings of ($0.14) per share and revenue of $61.58 million for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Esperion Therapeutics Stock Performance

ESPR stock traded down $0.03 during midday trading on Friday, hitting $1.83. 1,962,287 shares of the company's stock were exchanged, compared to its average volume of 4,141,908. Esperion Therapeutics has a one year low of $1.58 and a one year high of $3.94. The stock's fifty day moving average price is $2.08 and its 200-day moving average price is $2.10. The company has a market cap of $359.60 million, a PE ratio of -2.85 and a beta of 1.01.

Analyst Ratings Changes

ESPR has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $16.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, February 11th. StockNews.com downgraded shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 15th. The Goldman Sachs Group initiated coverage on shares of Esperion Therapeutics in a report on Wednesday, December 18th. They set a "neutral" rating and a $4.00 price objective on the stock. Cantor Fitzgerald started coverage on shares of Esperion Therapeutics in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $8.00 target price for the company. Finally, JMP Securities reissued a "market outperform" rating and issued a $4.00 price target (down previously from $7.00) on shares of Esperion Therapeutics in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $6.75.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.